Richard S. Geary

TL;DR: The majority of intracellular oligonucleotide distribution following systemic or local administration occurs rapidly in just a few hours following administration and is facilitated by rapid endocytotic uptake mechanisms, further understanding of the intrACEllular trafficking of oligon nucleotides may provide further enhancements in design and ultimate potency of antisense oligonucotides in the future.

TL;DR: A phase 1/2a first-in-man trial and a phase 2 trial aimed to assess the efficacy, safety, and tolerability of two unique antisense oligonucleotides designed to lower Lp(a) concentrations.

TL;DR: Oligonucleotides targeting mouse Angptl3 retarded the progression of atherosclerosis and reduced levels of atherogenic lipoproteins in mice and use of the same strategy to target human ANGPTL3 reduced levels in humans.

TL;DR: It is found that treatment with ISIS 304801 was associated with significant lowering of triglyceride levels, among patients with a broad range of baseline levels, through selective antisense inhibition of APOC3 synthesis.

TL;DR: The safety, pharmacokinetics, and pharmacodynamics of ISIS-APO (a)Rx, a second-generation antisense drug designed to reduce the synthesis of apolipoprotein(a) (apo[a]) in the liver, are assessed.